A Phase 3 interventional study of Zoster Vaccine, Live (AMP) and Zoster Vaccine, Live in Herpes Zoster and Shingles, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 7th largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 16th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2012.
This study's enrollment of 498 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2012, is one of 14 in phase 3, and was the 21st registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will determine whether ZOSTAVAX™ made with an alternative manufacturing process [ZOSTAVAX™ (AMP)] is well tolerated and immunogenic, and has a comparable immune response to ZOSTAVAX™.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZOSTAVAX™ manufactured with an alternative process
Biological: Zoster Vaccine, Live (AMP)
ZOSTAVAX™ manufactured with the current process
Biological: Zoster Vaccine, Live
One approximately 0.65-mL injection subcutaneously on Day 1
One approximately 0.65-mL injection subcutaneously on Day 1
Also known as: ZOSTAVAX™, V211
Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody
VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)
Time frame: Day 1 and Week 6 postvaccination
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers
VZV antibody titers were determined by gpELISA. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 6 / Day 1 (Baseline).
Time frame: Day 1 (Baseline) to Week 6 postvaccination
Number of Participants With One or More Adverse Experiences (AEs)
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.
Time frame: Day 1 to Day 42 postvaccination
Number of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination
An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement
Time frame: Day 1 to Day 42 postvaccination
Number of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination
An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement
Time frame: Day 1 to Day 182 postvaccination
| Milestone | ZOSTAVAX™ (AMP) | ZOSTAVAX™ |
|---|---|---|
| Started | 332 | 166 |
| Vaccinated | 331 | 166 |
| Completed | 329 | 166 |
| Not completed | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | ZOSTAVAX™ (AMP) | ZOSTAVAX™ |
|---|---|---|
| Started | 329 | 166 |
| Completed | 328 | 163 |
| Not completed | 1 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 |
VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)
| Units/mL | ZOSTAVAX™ (AMP) | ZOSTAVAX™ |
|---|---|---|
| Day 1 postvaccination; n = 330, 166 | 235.7 (211.7 to 262.5) | 208.2 (176.4 to 245.7) |
| Week 6 postvaccination; n = 320, 164 | 532.6 (489.2 to 579.9) | 457.1 (403.3 to 518.0) |
VZV antibody titers were determined by gpELISA. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 6 / Day 1 (Baseline).
| Ratio | ZOSTAVAX™ (AMP) | ZOSTAVAX™ |
|---|---|---|
| Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers | 2.3 (2.1 to 2.4) | 2.2 (2.0 to 2.5) |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.
| Participants | ZOSTAVAX™ (AMP) | ZOSTAVAX™ |
|---|---|---|
| Number of Participants With One or More Adverse Experiences (AEs) | 205 | 99 |
An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement
| Participants | ZOSTAVAX™ (AMP) | ZOSTAVAX™ |
|---|---|---|
| Number of Participants With One or More Serious Adverse Experience (SAE) Day 1 to 42 Postvaccination | 1 | 2 |
An SAE is defined as any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement
| Participants | ZOSTAVAX™ (AMP) | ZOSTAVAX™ |
|---|---|---|
| Number of Participants With One or More Serious Adverse Experience Day 1 to 182 Postvaccination | 4 | 8 |
Collected over Serious Adverse Events: Day 1 to Day 182 postvaccination; Other Adverse Events: Day 1 to Day 42 postvaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZOSTAVAX™ (AMP) | — | 4/330 (1.2%) | 186/330 (56.4%) |
| ZOSTAVAX™ | — | 8/166 (4.8%) | 85/166 (51.2%) |
| Event | ZOSTAVAX™ (AMP) | ZOSTAVAX™ |
|---|---|---|
| Bile duct stoneHepatobiliary disorders | 0/330 | 1/166 |
| Traumatic liver injuryInjury, poisoning and procedural complications | 0/330 | 1/166 |
| Cardiac failure congestiveCardiac disorders | 0/330 | 1/166 |
| VertigoEar and labyrinth disorders | 0/330 | 1/166 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/330 | 1/166 |
| Ileus paralyticGastrointestinal disorders | 0/330 | 1/166 |
| CholangitisHepatobiliary disorders | 0/330 | 1/166 |
| Gallbladder perforationHepatobiliary disorders | 0/330 | 1/166 |
| Enterocolitis infectiousInfections and infestations | 0/330 | 1/166 |
| ConcussionInjury, poisoning and procedural complications | 0/330 | 1/166 |
| Event | ZOSTAVAX™ (AMP) | ZOSTAVAX™ |
|---|---|---|
| Injection-site painGeneral disorders | 146/330 | 68/166 |
| Injection-site erythemaGeneral disorders | 135/330 | 66/166 |
| Injection-site swellingGeneral disorders | 106/330 | 53/166 |
| Injection-site pruritusGeneral disorders | 22/330 | 13/166 |
| Age, Continuous(years) | ZOSTAVAX™ (AMP) | ZOSTAVAX™ | Total |
|---|---|---|---|
| Mean | 62.9 ± 7.1 | 62.4 ± 7.0 | 62.8 ± 7.1 |
| Sex: Female, Male(Participants) | ZOSTAVAX™ (AMP) | ZOSTAVAX™ | Total |
|---|---|---|---|
| Female | 196 | 99 | 295 |
| Male | 136 | 67 | 203 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
The record gives a start of Apr 2012, a primary completion of Jul 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine